Héctor Camilo Pérez Cely

Héctor Camilo Pérez Cely

Auto-generated profile, based on publicly available information

Héctor Camilo Pérez Cely

Universidad Nacional de Colombia

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2022 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Open access
HPH.C. Pérez
H.C. Pérez
SMS. Morales
S. Morales
LEL. Enciso
L. Enciso
JCJ.A. Carreño
J.A. Carreño
XRX. Rueda
X. Rueda
Folliculotropic mycosis fungoides is a variant that has poor prognosis and a variable clinical presentation. Concerns have been expressed that the current TNMB staging of this tumor may not be useful. A recently developed classification system based on clinical and histologic variables classifies this tumor as early or advanced, a distinction found to correlate with prognosis. The aim of this study was to compare survival in FMF in Colombia between patients with early versus advanced tumors. Retrospective, observational study of clinical course and outcomes in patients with FMF treated at the National Cancer Institute of Colombia between 2008 and 2020. Survival was compared between early and advanced disease. Twenty-one patients (11 with early FMF and 10 with advanced FMF) were studied. Seven patients, all with advanced disease, died. Survival at 5 years was 62% overall and 40% for patients with advanced FMF. No differences were observed when survival was analyzed according to TNMB stage. TNMB staging is not useful in FMF. The new classification system based on clinicopathologic features appears to provide reliable information for assessing prognosis and guiding treatment decisions.

8 October 2022 in Actas Dermo-Sifiliograficas
Verified
Journal Article
Open access
HPH.C. Pérez
H.C. Pérez
SMS. Morales
S. Morales
LEL. Enciso
L. Enciso
JCJ.A. Carreño
J.A. Carreño
XRX. Rueda
X. Rueda
Folliculotropic mycosis fungoides is a variant that has poor prognosis and a variable clinical presentation. Concerns have been expressed that the current TNMB staging of this tumor may not be useful. A recently developed classification system based on clinical and histologic variables classifies this tumor as early or advanced, a distinction found to correlate with prognosis. The aim of this study was to compare survival in FMF in Colombia between patients with early versus advanced tumors. Retrospective, observational study of clinical course and outcomes in patients with FMF treated at the National Cancer Institute of Colombia between 2008 and 2020. Survival was compared between early and advanced disease. Twenty-one patients (11 with early FMF and 10 with advanced FMF) were studied. Seven patients, all with advanced disease, died. Survival at 5 years was 62% overall and 40% for patients with advanced FMF. No differences were observed when survival was analyzed according to TNMB stage. TNMB staging is not useful in FMF. The new classification system based on clinicopathologic features appears to provide reliable information for assessing prognosis and guiding treatment decisions.

1 October 2019 in Italian Journal of Dermatology and Venereology
Verified
Journal Article
Closed access
HCHéctor C. Pérez Cely
Héctor C. Pérez Cely
ERElkin J. Casadiego Rincón
Elkin J. Casadiego Rincón
HLHéctor J. Castellanos Lorduy
Héctor J. Castellanos Lorduy
BACKGROUND: Bacterial resistance to antibiotics has been growing exponentially. Acne is the most common outpatient complains in dermatology, and involve the use of antibiotics for treatment. METHODS: We conducted a drug utilization study, with a retrospective and descriptive design, in order to evaluated the antibiotic prescription pattern for acne vulgaris patients who were cared for the first time in 2015, and were prescribed with an antibiotic, no matter if it was topical, oral or both, and compared it against the Colombian clinical practice guidelines valid for that year in our country. RESULTS: Three hundred sixty-nine patients were randomly collected, 221 women and 148 men. There were a correct adherence to guidelines in election of an antibiotic, its dosage, and time of use in 51.7%, 94.85%, and 76.1%, respectively. 37.1% of patients has being correctly prescribe globally, taking into consideration the three previously describe variables. CONCLUSIONS: A no adherent antibiotic prescription was documented for less than half of the patients. In almost a quarter of the patients it was not prescribed for the right time and in most patients the correct dose was chosen. It is important to know the prescription pattern as it allows decisions to be made that lead to an adequate use of antibiotics, and thus prevent the development of antimicrobial resistance.

15 October 2025 in Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Verified
Journal Article
Open access
PDF file
MTMelanie Alejandra Villamizar Téllez
Melanie Alejandra Villamizar Téllez
HCHéctor Camilo Pérez Cely
Héctor Camilo Pérez Cely
Desde los primeros registros precolombinos hasta las terapias celulares personalizadas, la dermatología oncológica ha recorrido un camino extraordinario.

1 October 2026 in Revista de la Facultad de Medicina
Verified
Journal Article
Open access
PDF file
CACristian David Arevalo-Mojica
Cristian David Arevalo-Mojica
DADaniel Arboleda
Daniel Arboleda
HPHéctor Camilo Pérez-Cely
Héctor Camilo Pérez-Cely
NTNicolas Arnulfo Torres-Muñoz
Nicolas Arnulfo Torres-Muñoz
MBMarcela Barbosa-Pérez
Marcela Barbosa-Pérez
Introduction: Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome is a severe, life-threatening adverse drug reaction that causes multiorgan involvement characterized by rash, fever, lymphadenopathy, and eosinophilia. Only one case of fenofibrate-associated DRESS syndrome has been reported in the literature. Case presentation: A 70-year-old man with hypertension and hypertriglyceridemia presented to the emergency department of a university hospital in Bogotá (Colombia) with a generalized erythematous rash, intermittent fever (38.6°C), diarrhea, nausea, and palpitations over the preceding 3 days. The patient reported initiating fenofibrate (160 mg/day) 2 weeks prior for hypertriglyceridemia management. Admission laboratory tests revealed eosinophilia and elevated transaminases. The patient scored 4 according to RegiSCAR criteria, consistent with a probable case of fenofibrate-associated DRESS syndrome, so he was admitted. The drug was immediately discontinued, and IV methylprednisolone (250 mg/day) was initiated for 3 days, followed by oral prednisolone (1 mg/kg/day) with a planned taper. On hospital day 7, following favorable clinical progress (progressive improvement of skin lesions and normalization of eosinophil count), he was discharged with instructions to continue oral prednisolone on a gradual 8-week taper, during which no relapses or adverse events occurred. Conclusion: This case highlights the importance of timely recognition of DRESS syndrome clinical manifestations and prompt identification of the suspected drug, even when rarely implicated, such as fenofibrate. It is still worth noting that, based on the RegiSCAR score, this represents a probable, rather than a definitive, case of fenofibrate-associated DRESS syndrome.

24 November 2023 in Revista de la Asociación Colombiana de Dermatología y Cirugía Dermatológica
Verified
Journal Article
Open access
PDF file
GFGabriella González Franco
Gabriella González Franco
HHHugo Eduardo Herrera
Hugo Eduardo Herrera
ÁHÁlvaro Acosta-De Haart
Álvaro Acosta-De Haart
HPHéctor Camilo Pérez-Cely
Héctor Camilo Pérez-Cely
El fibroxantoma atípico (FXA) es un tumor que aparece en pacientes de edad avanzada, con antecedente de fotoexposición, con mayor incidencia de casos en cabeza y cuello. Es una neoplasia dérmica, no presenta invasión de tejido subcutáneo o linfovascular ni perineural. Son tumores conformados por células histiocitoides, fusiformes, epitelioides y gigantes multinucleadas con núcleos pleomórficos. No existen cifras epidemiológicas respecto a la incidencia en Colombia, sin embargo se ha reportado que la incidencia del FXA en España es de 0,59 casos/100,000 habitantes, por ende se reconoce que es una lesión tumoral de baja incidencia. (1) A continuación se realiza un reporte de 3 casos de pacientes quienes presentaron un fibroxantoma atípico en diferentes localizaciones anatómicas.